FDA
label_change
· 2023-06-05
FDA Approved: PREVYMIS — Supplemental Application (Merck Sharp & Dohme LLC)
Summary
FDA approved a supplemental application for PREVYMIS (letermovir) submitted by Merck, resulting in changes to its labeling.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for PREVYMIS (LETERMOVIR)